The agenda for the 14 May 2014 Transparency Commission meeting is now available.  The Commission will examine the following medicines:

• Eprelenone (Inspra) - Re-evaluation of SMR & ASMR
• Oestradiol hemihydrate with dydrogesterone (Climaston) - New strength
• Panitumumab (Vectibix) - Review of current entry
• Imatinib mesylate (Glivec) - New indication
• Darunavir ethanolate (Prezista) - New indication
• Loxapine (Adasuve) - New medicine

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-05/odj_ct_14042014_internet.pdf